FDA Approves Expanded Age Indication for RSV Vaccine

by | Mar 17, 2026 | Health

Spread the love
The FDA has approved expanded use of Arexvy, an RSV vaccine, for those aged 18-49 at increased LRTD risk.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments